MFTH Medisafe 1 Technologies Locking Syringe Adds ERP Compatibility

http://www.equitygroups.com/index.php?a=topic&t=168647

"Customizing our syringe locking device to work with ERP systems, enables a hospital to keep more accurate records, and eliminates additional possibilities for human error in the administration of medications via syringe," said, Jacob Elhadad, CEO of Medisafe 1 Technologies.

"The combination of the system's simple locking device with state of the art record tracking works to protect hospitals and their patients. We are confident that hospitals will recognize the value of our patented system."

See this Amp at http://bit.ly/hyMapl

WellTek Subsidiary Unveils Platform for Integrating Network Marketing With

http://www.equitygroups.com/index.php?a=topic&t=168645

"Until now, social network users have had no way to leverage their personal network as a direct income opportunity. Today, we've changed that," said David George, CEO of WellCity. "We are the first social network to offer actual money to its users. With the integration of WellCity Market, our WellCity 'residents' have an unprecedented opportunity to help others achieve optimal health, while they earn income from the purchases made by their network of family and friends or 'neighbors.' It's a simple idea: users get paid every time their 'neighbors' make a purchase inside WellCity Market."

See this Amp at http://bit.ly/h0h8jH

ZBB Stock News ZBB Energy Reiterates Strong and Growing Backlog

http://www.equitygroups.com/index.php?a=topic&t=168631#p0

Insiders Accumulate Significant Ownership Positions in ZBB Energy

See this Amp at http://bit.ly/hDyOE5

Keryx Biopharmaceuticals Announces Highly Statistically Significant

http://www.equitygroups.com/index.php?a=topic&t=168638

KERX : announced positive top-line results from the Phase 3 short-term efficacy study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. In this study, conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), Zerenex met the study's primary endpoint, described below, demonstrating a...

See this Amp at http://bit.ly/hUSdBd

OmniVision Starts Mass Production of UltraCompact OV6930 Medical Image

http://www.equitygroups.com/index.php?a=topic&t=168637

..."Additionally, our advanced pixel design and proven manufacturing process keep our products affordable, allowing medical devices to be made disposable while increasing patient safety, operating room hygiene and ease-of-use for medical practitioners."...

See this Amp at http://bit.ly/dHgA3o

OVTI OmniVision Launches Feature Rich 8 Megapixel RAW CMOS Image Sensor for the

http://www.equitygroups.com/index.php?a=topic&t=168636

One of the advanced features of the OV8820 is an integrated scaler, which enables EIS and maintains full FOV with improved signal-to-noise performance in 1080p HD video mode operating at 30 fps. Another key image processing feature is a 2 x 2 binning functionality with a post-binning re-sampling filter function that minimizes spatial artifacts and removes image artifacts around edges to deliver clean, crisp color images. This is...

See this Amp at http://bit.ly/eQkPcF

Ocean Power Technologies Expands Relationship with Mitsui Engineering

http://www.equitygroups.com/index.php?a=topic&t=168632

Ocean Power Technologies, Inc. (Nasdaq: OPTT and London Stock Exchange AIM: OPT) ("OPT" or the "Company") is pleased to announce that it has expanded its relationship with Mitsui Engineering & Shipbuilding Co. Ltd. (“MES”) with the signing of a new contract to develop OPT’s PowerBuoy technology for its application in Japanese sea conditions. ......

See this Amp at http://bit.ly/fzOCdk